Le Lézard
Classified in: Health, Science and technology
Subject: PER

Disc Medicine Appoints William White to its Board of Directors


CAMBRIDGE, Mass., Jan. 13, 2021 /PRNewswire/ -- Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that it has appointed William White to its Board of Directors.

"We are delighted to welcome Bill to Disc Medicine's Board of Directors," said Chief Executive Officer John Quisel, JD, PhD. "Bill is joining at an exciting time in our company's story as we progress our first program DISC-0974 into the clinic this year. His breadth of experience and financial acumen will be invaluable as we enter this period of growth."

Mr. White is currently the Chief Financial Officer and Head of Corporate Development at Akero Therapeutics.  Prior to joining Akero, he spent 18 years as a life sciences-focused Investment Banker in New York and London.  He was most recently Head of U.S. Life Sciences Investment Banking at Deutsche Bank, and previously worked at Goldman Sachs and Citigroup.  Prior to his time on Wall Street, he was a Law Clerk to the Honorable Kimba M. Wood of the Southern District of New York and an attorney at Sullivan & Cromwell.  He holds an A.B. from Princeton, an M.P.P. from Harvard and a J.D. from Columbia.

"I am excited to join the board of Disc Medicine during this period of growth and have been impressed by the dedication, passion and quality of the team," Mr. White commented. "I am looking forward to sharing my experience and expertise as Disc executes on its vision of building a leading hematology company." 

As part of his Board responsibilities, Mr. White will serve on Disc Medicine's Audit Committee as its Chair.

About Disc Medicine

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients who suffer from hematologic disorders. The company is harnessing new insights in the biology of hepcidin, the master regulator of iron metabolism, to develop a portfolio of first-in-class therapeutic candidates to treat anemias and other diseases caused by iron dysregulation. For more information, visit www.discmedicine.com.

SOURCE Disc Medicine


These press releases may also interest you

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...

at 17:31
DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market...

at 17:00
Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings. SONIFI Health is a leading U.S. healthcare technology company based in Sioux...

at 17:00
A record 3,618 graduating students and physicians matched to residency training programs in Canada in this year's R-1 Main Residency Match (R-1 match), the Canadian Resident Matching Service (CaRMS) announced today....



News published on and distributed by: